Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402

Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402

<p>Abstract</p> <p>Background</p> <p>The tumor associated antigen (TAA) gp100 was one of the first identified and has been used in clinical trials to treat melanoma patients. However, the gp100 epitope peptide restricted to HLA-A*2402 has not been extensively examined c...

Full description

Bibliographic Details
Main Authors: Baba Toshiyuki, Sato-Matsushita Marimo, Kanamoto Akira, Itoh Akihiko, Oyaizu Naoki, Inoue Yusuke, Kawakami Yutaka, Tahara Hideaki
Format: Article
Language:English
Published: BMC 2010-09-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/8/1/84

Internet

http://www.translational-medicine.com/content/8/1/84

Similar Items